Kfh - Riverside
- Type
- Teaching hospital
- Where
- Riverside, CA
- Medicare CCN
- 050686
- Received
- $502,839 in 81 records, 2025 ($2,091 general, $500,747 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 2 | $2,091 |
| 2025 | Research payment | 79 | $500,747 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Janssen Research & Development, LLC | 66 | $457,065 | 2025 |
| Shockwave Medical, Inc | 8 | $25,139 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $18,543 | 2025 |
| Medical Device Business Services, Inc. | 1 | $1,130 | 2025 |
| Zimmer Biomet Holdings, Inc. | 1 | $961 | 2025 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 79 | $500,747 |
| Grant | 1 | $1,130 |
| Debt forgiveness | 1 | $961 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-25 | Janssen Research & Development, LLC | $405 | Research payment | Cash or cash equivalent | A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Co | 2025 | |
| 2025-12-24 | Janssen Research & Development, LLC | $3,939 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 | |
| 2025-12-19 | Janssen Research & Development, LLC | $26,681 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 | |
| 2025-12-17 | Janssen Research & Development, LLC | $9,756 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 | |
| 2025-12-17 | Janssen Research & Development, LLC | $2,004 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 | |
| 2025-12-05 | Shockwave Medical, Inc | $5,326 | Research payment | Cash or cash equivalent | Equity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease | 2025 | |
| 2025-11-14 | Janssen Research & Development, LLC | $24,481 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 | |
| 2025-10-30 | Janssen Research & Development, LLC | $1,532 | Research payment | Cash or cash equivalent | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv | 2025 | |
| 2025-10-30 | Janssen Research & Development, LLC | $1,200 | Research payment | Cash or cash equivalent | A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Co | 2025 | |
| 2025-10-30 | Janssen Research & Development, LLC | $750 | Research payment | Cash or cash equivalent | A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Co | 2025 | |
| 2025-10-22 | Janssen Research & Development, LLC | $3,960 | Research payment | Cash or cash equivalent | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv | 2025 | |
| 2025-10-20 | Janssen Research & Development, LLC | $8,784 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 | |
| 2025-10-20 | Janssen Research & Development, LLC | $1,967 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 | |
| 2025-10-20 | Shockwave Medical, Inc | $1,200 | Research payment | Cash or cash equivalent | Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II | 2025 | |
| 2025-10-17 | Janssen Research & Development, LLC | $2,250 | Research payment | Cash or cash equivalent | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv | 2025 | |
| 2025-10-17 | Janssen Research & Development, LLC | $750 | Research payment | Cash or cash equivalent | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv | 2025 | |
| 2025-10-16 | Janssen Research & Development, LLC | $23,181 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 | |
| 2025-10-14 | Janssen Research & Development, LLC | $4,648 | Research payment | Cash or cash equivalent | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv | 2025 | |
| 2025-10-13 | Janssen Research & Development, LLC | $2,700 | Research payment | Cash or cash equivalent | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv | 2025 | |
| 2025-10-13 | Janssen Research & Development, LLC | $2,000 | Research payment | Cash or cash equivalent | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv | 2025 | |
| 2025-10-13 | Janssen Research & Development, LLC | $1,815 | Research payment | Cash or cash equivalent | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv | 2025 | |
| 2025-10-13 | Janssen Research & Development, LLC | $1,500 | Research payment | Cash or cash equivalent | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv | 2025 | |
| 2025-10-13 | Janssen Research & Development, LLC | $1,500 | Research payment | Cash or cash equivalent | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv | 2025 | |
| 2025-10-13 | Janssen Research & Development, LLC | $1,500 | Research payment | Cash or cash equivalent | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv | 2025 | |
| 2025-10-13 | Janssen Research & Development, LLC | $1,500 | Research payment | Cash or cash equivalent | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv | 2025 | |
| 2025-09-29 | Janssen Research & Development, LLC | $152 | Research payment | Cash or cash equivalent | A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Co | 2025 | |
| 2025-09-25 | Janssen Research & Development, LLC | $6,336 | Research payment | Cash or cash equivalent | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv | 2025 | |
| 2025-09-25 | Shockwave Medical, Inc | $345 | Research payment | Cash or cash equivalent | Equity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease | 2025 | |
| 2025-09-19 | Janssen Research & Development, LLC | $22,400 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 | |
| 2025-09-19 | Janssen Research & Development, LLC | $5,952 | Research payment | Cash or cash equivalent | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv | 2025 | |
| 2025-09-19 | Janssen Research & Development, LLC | $4,298 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 | |
| 2025-09-17 | Zimmer Biomet Holdings, Inc. | $961 | Debt forgiveness | Cash or cash equivalent | 2025 | ||
| 2025-09-12 | Shockwave Medical, Inc | $1,698 | Research payment | Cash or cash equivalent | Equity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease | 2025 | |
| 2025-09-03 | Janssen Research & Development, LLC | $1,200 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 | |
| 2025-08-20 | Janssen Research & Development, LLC | $12,514 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 | |
| 2025-08-11 | Janssen Research & Development, LLC | $405 | Research payment | Cash or cash equivalent | A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Co | 2025 | |
| 2025-08-06 | Shockwave Medical, Inc | $4,500 | Research payment | Cash or cash equivalent | Equity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease | 2025 | |
| 2025-07-28 | Janssen Research & Development, LLC | $21,024 | Research payment | Cash or cash equivalent | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv | 2025 | |
| 2025-07-28 | Janssen Research & Development, LLC | $10,133 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 | |
| 2025-07-11 | Janssen Research & Development, LLC | $2,000 | Research payment | Cash or cash equivalent | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv | 2025 | |
| 2025-07-11 | Janssen Research & Development, LLC | $1,500 | Research payment | Cash or cash equivalent | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv | 2025 | |
| 2025-07-11 | Janssen Research & Development, LLC | $550 | Research payment | Cash or cash equivalent | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv | 2025 | |
| 2025-07-07 | Janssen Research & Development, LLC | $7,138 | Research payment | Cash or cash equivalent | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv | 2025 | |
| 2025-07-07 | Janssen Research & Development, LLC | $4,500 | Research payment | Cash or cash equivalent | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv | 2025 | |
| 2025-07-07 | Janssen Research & Development, LLC | $1,600 | Research payment | Cash or cash equivalent | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv | 2025 | |
| 2025-07-07 | Janssen Research & Development, LLC | $675 | Research payment | Cash or cash equivalent | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv | 2025 | |
| 2025-07-07 | Janssen Research & Development, LLC | $150 | Research payment | Cash or cash equivalent | A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Co | 2025 | |
| 2025-07-07 | Janssen Research & Development, LLC | $90 | Research payment | Cash or cash equivalent | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv | 2025 | |
| 2025-06-18 | Shockwave Medical, Inc | $355 | Research payment | Cash or cash equivalent | Equity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease | 2025 | |
| 2025-06-13 | Janssen Research & Development, LLC | $16,315 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 | |
| 2025-06-09 | Janssen Research & Development, LLC | $557 | Research payment | Cash or cash equivalent | A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Co | 2025 | |
| 2025-05-20 | Janssen Research & Development, LLC | $6,062 | Research payment | Cash or cash equivalent | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv | 2025 | |
| 2025-05-16 | Janssen Research & Development, LLC | $9,331 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 | |
| 2025-05-12 | Janssen Research & Development, LLC | $350 | Research payment | Cash or cash equivalent | A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Co | 2025 | |
| 2025-04-28 | Janssen Research & Development, LLC | $19,008 | Research payment | Cash or cash equivalent | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv | 2025 | |
| 2025-04-28 | Janssen Research & Development, LLC | $16,625 | Research payment | Cash or cash equivalent | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv | 2025 | |
| 2025-04-28 | Janssen Research & Development, LLC | $4,000 | Research payment | Cash or cash equivalent | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv | 2025 | |
| 2025-04-28 | Janssen Research & Development, LLC | $3,500 | Research payment | Cash or cash equivalent | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv | 2025 | |
| 2025-04-24 | Shockwave Medical, Inc | $180 | Research payment | Cash or cash equivalent | Equity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease | 2025 | |
| 2025-04-21 | Janssen Research & Development, LLC | $3,477 | Research payment | Cash or cash equivalent | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv | 2025 | |
| 2025-04-21 | Janssen Research & Development, LLC | $1,350 | Research payment | Cash or cash equivalent | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv | 2025 | |
| 2025-04-18 | Janssen Research & Development, LLC | $13,714 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 | |
| 2025-04-17 | Janssen Research & Development, LLC | $1,299 | Research payment | Cash or cash equivalent | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv | 2025 | |
| 2025-04-15 | Janssen Research & Development, LLC | $61,695 | Research payment | Cash or cash equivalent | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv | 2025 | |
| 2025-04-11 | Janssen Research & Development, LLC | $750 | Research payment | Cash or cash equivalent | A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Co | 2025 | |
| 2025-03-24 | Medical Device Business Services, Inc. | $1,130 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-03-19 | Janssen Research & Development, LLC | $12,447 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 | |
| 2025-03-19 | Bayer Healthcare Pharmaceuticals Inc. | $6,300 | Research payment | Cash or cash equivalent | Eylea Drug, Other | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Afliberc | 2025 |
| 2025-03-19 | Bayer Healthcare Pharmaceuticals Inc. | $2,000 | Research payment | Cash or cash equivalent | Eylea Drug, Other | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Afliberc | 2025 |
| 2025-03-19 | Bayer Healthcare Pharmaceuticals Inc. | $750 | Research payment | Cash or cash equivalent | Eylea Drug, Other | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Afliberc | 2025 |
| 2025-03-17 | Bayer Healthcare Pharmaceuticals Inc. | $8,993 | Research payment | Cash or cash equivalent | Eylea Drug, Other | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Afliberc | 2025 |
| 2025-03-17 | Bayer Healthcare Pharmaceuticals Inc. | $500 | Research payment | Cash or cash equivalent | Eylea Drug, Other | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Afliberc | 2025 |
| 2025-03-06 | Janssen Research & Development, LLC | $650 | Research payment | Cash or cash equivalent | A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Co | 2025 | |
| 2025-03-06 | Janssen Research & Development, LLC | $456 | Research payment | Cash or cash equivalent | A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Co | 2025 | |
| 2025-02-28 | Janssen Research & Development, LLC | $405 | Research payment | Cash or cash equivalent | A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Co | 2025 | |
| 2025-02-19 | Janssen Research & Development, LLC | $14,090 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 | |
| 2025-02-05 | Janssen Research & Development, LLC | $5,250 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 | |
| 2025-02-04 | Shockwave Medical, Inc | $11,534 | Research payment | Cash or cash equivalent | Equity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease | 2025 | |
| 2025-01-30 | Janssen Research & Development, LLC | $18,500 | Research payment | Cash or cash equivalent | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv | 2025 | |
| 2025-01-30 | Janssen Research & Development, LLC | $4,000 | Research payment | Cash or cash equivalent | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv | 2025 | |
| 2025-01-17 | Janssen Research & Development, LLC | $11,814 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Riverside, CA, county Riverside County, CA, state California; placed by its city name.
| Measure | Place (city or town) Riverside, CA | County Riverside County, CA | State California |
|---|---|---|---|
| Population B01003 | 319,069 | 2,478,600 | 39,287,377 |
| Population, 2020 census P1 | 314,998 | 2,418,185 | 39,538,223 |
| Median age B01002 | 33.6 | 37.0 | 37.9 |
| Under 18 B01001 | 23.1% | 24.1% | 22.0% |
| 65 and over B01001 | 12.0% | 15.4% | 15.7% |
| Households B11001 | 95,176 | 775,335 | 13,548,091 |
| Foreign born B05002 | 22.4% | 21.9% | 27.0% |
| Median household income B19013 | $91,045 | $93,074 | $99,122 |
| Median family income B19113 | $101,253 | $103,984 | $113,346 |
| Per capita income B19301 | $34,896 | $38,317 | $49,513 |
| Poverty rate B17001 | 12.2% | 10.6% | 12.0% |
| Unemployment rate B23025 | 6.3% | 6.5% | 6.6% |
| Civilian labor force B23025 | 164,887 | 1,191,323 | 20,068,466 |
| Mean commute (minutes) B08013 | 31.3 | 33.8 | 28.7 |
| Bachelor's degree or higher B15003 | 25.7% | 25.6% | 37.1% |
| Housing units B25001 | 99,910 | 869,414 | 14,644,735 |
| Owner-occupied B25003 | 56.8% | 69.1% | 55.9% |
| Renters B25003 | 43.2% | 30.9% | 44.1% |
| Median home value B25077 | $584,800 | $557,300 | $734,700 |
| Median gross rent B25064 | $1,914 | $1,901 | $2,036 |
| White, not Hispanic B03002 | 26.1% | 31.0% | 33.8% |
| Black B03002 | 5.9% | 6.0% | 5.2% |
| Hispanic or Latino B03002 | 55.6% | 51.3% | 40.2% |
| Asian B03002 | 8.0% | 6.9% | 15.3% |
| American Indian and Alaska Native B03002 | 0.2% | 0.3% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Riverside, CA.
Comments